Gene Type Associated with Higher Risk of Celiac Disease
|
By LabMedica International staff writers Posted on 10 Jul 2014 |
Researcher have found that children born with 2 copies of a high-risk variant in a specific group of genes confers 26% chance of developing celiac disease autoimmunity (CDA), an early sign of celiac disease (CD), by age 5. They also found a higher celiac risk in Sweden than in the three other studied countries, even with the same genetic risk factors.
The Environmental Determinants of Diabetes in Youth consortium (TEDDY) is studying CD and type-1 diabetes because both are autoimmune diseases with some of the same genetic risk factors. CD (which stems from an immune reaction to gluten) occurs in just under 1% of the USA population, and is more common than type-1 diabetes. The celiac study followed 6,403 newborn children with either of two high-risk gene groups important for immune function—HLA-DR3-DQ2 or HLA-DR4-DQ8—to see who would develop CD or CDA. These genes are involved in presenting gluten to immune cells. Over five years, 291 developed CD, while another 786 developed CDA.
“By looking at the genes of the children who participated in TEDDY, we can now identify who among them is at highest risk for CD, and their parents and health care providers can monitor these children to detect the disease early,” said Beena Akolkar, PhD, project scientist for TEDDY at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; primary funder of TEDDY) of the US National Institutes of Health (NIH; Bethesda, MD, USA).
Researchers found that youth with 2 copies of HLA-DR3-DQ2 had the highest likelihood of disease development by age 5. Of this group, 26% developed CDA by age 5 and 12% developed CD. In those with 1 copy of HLA-DR3-DQ2, the risks of CDA and CD by age 5 were 11% and 3%, respectively. About 90% of CD patients carry HLA-DR3-DQ2.
Based on earlier research, lower rates of CDA and CD were expected in the USA and Germany than in Sweden. Rates of CDA in Sweden were nearly double the USA rates. However, the researchers were surprised to discover that Sweden also had higher rates of CDA and CD than Finland. “We’ve long known that Sweden has a high incidence of CD, but we don’t yet know why. TEDDY’s unique structure of having the same protocol in several countries enables us to search for factors that trigger the disease,” said the paper’s senior author Daniel Agardh, MD, PhD, of Lund University in Sweden, “By studying similarities and differences between genes and environmental factors in these countries, we hope to pinpoint risk factors for the disease.” This study will include examining how diet affects bacteria in the gut and the immune system of children with differing genetic risks.
The primary goal of TEDDY is to find the causes of type-1 diabetes—why some children with high-risk genes for type-1 diabetes go on to develop the disease while others with the same genetic risk do not. “With research networks like TEDDY, NIH is actively seeking to understand how diseases like celiac and type-1 diabetes occur and, by using genetic screening and other tools, to develop a more personalized approach to disease prevention and treatment,” said NIDDK Director Griffin P. Rodgers, MD.
The study was reported by Liu E. et al. in the New England Journal of Medicine, July 3, 2014.
Related Links:
National Institutes of Health
The Environmental Determinants of Diabetes in Youth consortium (TEDDY)
Celiac disease
The Environmental Determinants of Diabetes in Youth consortium (TEDDY) is studying CD and type-1 diabetes because both are autoimmune diseases with some of the same genetic risk factors. CD (which stems from an immune reaction to gluten) occurs in just under 1% of the USA population, and is more common than type-1 diabetes. The celiac study followed 6,403 newborn children with either of two high-risk gene groups important for immune function—HLA-DR3-DQ2 or HLA-DR4-DQ8—to see who would develop CD or CDA. These genes are involved in presenting gluten to immune cells. Over five years, 291 developed CD, while another 786 developed CDA.
“By looking at the genes of the children who participated in TEDDY, we can now identify who among them is at highest risk for CD, and their parents and health care providers can monitor these children to detect the disease early,” said Beena Akolkar, PhD, project scientist for TEDDY at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; primary funder of TEDDY) of the US National Institutes of Health (NIH; Bethesda, MD, USA).
Researchers found that youth with 2 copies of HLA-DR3-DQ2 had the highest likelihood of disease development by age 5. Of this group, 26% developed CDA by age 5 and 12% developed CD. In those with 1 copy of HLA-DR3-DQ2, the risks of CDA and CD by age 5 were 11% and 3%, respectively. About 90% of CD patients carry HLA-DR3-DQ2.
Based on earlier research, lower rates of CDA and CD were expected in the USA and Germany than in Sweden. Rates of CDA in Sweden were nearly double the USA rates. However, the researchers were surprised to discover that Sweden also had higher rates of CDA and CD than Finland. “We’ve long known that Sweden has a high incidence of CD, but we don’t yet know why. TEDDY’s unique structure of having the same protocol in several countries enables us to search for factors that trigger the disease,” said the paper’s senior author Daniel Agardh, MD, PhD, of Lund University in Sweden, “By studying similarities and differences between genes and environmental factors in these countries, we hope to pinpoint risk factors for the disease.” This study will include examining how diet affects bacteria in the gut and the immune system of children with differing genetic risks.
The primary goal of TEDDY is to find the causes of type-1 diabetes—why some children with high-risk genes for type-1 diabetes go on to develop the disease while others with the same genetic risk do not. “With research networks like TEDDY, NIH is actively seeking to understand how diseases like celiac and type-1 diabetes occur and, by using genetic screening and other tools, to develop a more personalized approach to disease prevention and treatment,” said NIDDK Director Griffin P. Rodgers, MD.
The study was reported by Liu E. et al. in the New England Journal of Medicine, July 3, 2014.
Related Links:
National Institutes of Health
The Environmental Determinants of Diabetes in Youth consortium (TEDDY)
Celiac disease
Latest Molecular Diagnostics News
- FDA Clears At-Home HPV Test with Extended Genotyping for Cervical Screening
- Extracellular Vesicle RNA Biomarkers Enable Noninvasive IBD Diagnosis and Monitoring
- New Gene Signature Reveals Underdiagnosed Lung Cancer Subtype
- Genome Sequencing Identifies Noncoding Variants Causing Neonatal Diabetes
- Genetic Markers Predict GLP-1 Weight-Loss Response and Side Effects
- Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
- Mesothelioma in Younger Adults Linked to Genetic Risk Factors
- Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
- Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
- Simple Blood Test Enables Multi-Disease Detection from Single Sample
- Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
- Blood-Based ctDNA Test Enhances Risk Assessment in HPV-Related Throat Cancer
- WGS MCED Assay Demonstrates Rising Sensitivity and High Specificity
- ctDNA MRD Test Identifies Breast Cancer Patients Who May Avoid Surgery
- Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
- RNA Profiling Uncovers Therapeutic Targets in Solid Tumors
Channels
Clinical Chemistry
view channel
AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
Cardiovascular diseases are a leading cause of death, responsible for nearly 20 million deaths each year. Timely triage of myocardial infarction and heart failure hinges on rapid cardiac biomarker measurement,... Read moreNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read moreHematology
view channel
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read more
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read moreImmunology
view channel
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read moreMicrobiology
view channel
RNA-Based Workflow Identifies Active Skin Microbes for Dermatology Research
Human skin carries diverse microbial communities that influence barrier function and inflammation, yet identifying which organisms are metabolically active has been challenging. DNA-based surveys catalog... Read more
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read morePathology
view channelAI Improves Completeness of Complex Cancer Pathology Reports
Oncology teams increasingly rely on pathology reports that integrate histopathology, immunohistochemistry, and rapidly expanding biomarker testing. As patients live longer and undergo repeated analyses... Read more
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
Noninvasive Sputum Test Detects Early Lung Cancer
Early detection remains critical for improving outcomes in lung cancer, yet clinicians increasingly encounter indeterminate pulmonary nodules found incidentally or through screening, complicating decision-making.... Read more
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel







